Use of 52-mg Levonorgestrel-Releasing Intrauterine System in Adolescents and Young Adult Women: 3-Year Follow-Up

被引:4
|
作者
Oliveira, Elaine Cristina Fontes de [1 ,2 ]
Baeta, Thais [1 ,2 ]
Cotta, Rossana Cristina Fontes [3 ]
Rocha, Ana Luiza Lunardi [1 ,2 ,4 ]
机构
[1] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
[3] Hosp Vila Serra, Dept Pediat, Belo Horizonte, MG, Brazil
[4] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Ave Prof Alfredo Balena 190,St Efigenia, BR-30130100 Belo Horizonte, MG, Brazil
关键词
Key Words; Levonorgestrel-releasing intrauterine system; Long-acting reversible contraception; LARC; Intrauterine contraceptives; Adolescents; Amenorrhea rates; Uterine bleeding; Contraception; UNINTENDED PREGNANCY; COST-EFFECTIVENESS; CONTRACEPTION; CONTINUATION; BARRIERS; HEALTH; CARE; AGE;
D O I
10.1016/j.jpag.2022.09.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: To evaluate continuance rates, bleeding patterns, and patient satisfaction with 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) use in adolescents and young adult women during the first 3 years of useDesign: We conducted an observational prospective study.Setting: Family Planning Service of a tertiary hospital in Brazil Participants: One hundred adolescents and young women aged 16-24 years.Intervention: Insertion of 52-mg LNG-IUS for the main purpose of contraception. Follow-up visits were conducted at 12, 24, and 36 months after insertion.Main Outcome Measures: Continuance rates, reasons for discontinuation of the method, and women's satisfaction and bleeding patternsResults: Among those who were not lost to follow-up, LNG-IUS continuance rates were 89.1% (82/92), 82.9% (72/87), and 75.3% (64/85) in the first, second, and third years of use, respectively. The main reason for discontinuation was acne, followed by expulsion of/malpositioned LNG-IUS. Other reasons for discontinuation were irregular uterine bleeding, dysmenorrhea, and abdominal pain. The amenorrhea rates were 50%, 54.1%, and 39% at 12, 24, and 36 months, respectively. Spotting rates increased during the first 3 years of use (20.8%, 16.7%, and 26.6%, respectively). Adolescents and young women using the LNG-IUS showed high rates of satisfaction, with 93.9%, 100%, and 96.8% of women being very satisfied/satisfied in the first 3 years of use. Only 2 participants who continued using the LNG-IUS reported being very dissatisfied/dissatisfied in the third year of follow-up.Conclusion: The LNG-IUS showed high rates of continuation and satisfaction in the first 3 years of use in Brazilian adolescents and young adults. Most women reported a favorable bleeding pattern.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [1] A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system
    Petta, Carlos A.
    Ferriani, Rui A.
    Abrao, Mauricio S.
    Hassan, Daniela
    Rosa e Silva, Julio C.
    Podgaec, Silvio
    Bahamondes, Luis
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 143 (02) : 128 - 129
  • [2] Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease
    Ueda, Yusuke
    Kamiya, Chizuko A.
    Horiuchi, Chinami
    Miyoshi, Takekazu
    Hazama, Ryoichi
    Tsuritani, Mitsuhiro
    Iwanaga, Naoko
    Neki, Reiko
    Ikeda, Tomoaki
    Yoshimatsu, Jun
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (02) : 382 - 388
  • [3] Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system
    Eisenberg, David L.
    Schreiber, Courtney A.
    Turok, David K.
    Teal, Stephanie B.
    Westhoff, Carolyn L.
    Creinin, Mitchell D.
    CONTRACEPTION, 2015, 92 (01) : 10 - 16
  • [4] Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena®):: a 3-year follow-up study
    Baldaszti, E
    Wimmer-Puchinger, B
    Löschke, K
    CONTRACEPTION, 2003, 67 (02) : 87 - 91
  • [5] Five-year Contraceptive Use of 52-mg Levonorgestrel Releasing Intrauterine System in Young Women, Menstrual Patterns, and New Contraceptive Choice
    de Oliveira, Elaine Cristina Fontes
    Rocha, Ana Luiza Lunardi
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2023, 45 (11): : 654 - 660
  • [6] Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy
    Suhonen, S
    Holmstrom, T
    Lahteenmaki, P
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1997, 76 (02) : 145 - 150
  • [7] Reasons for satisfaction with the use of the 52-mg levonorgestrel intrauterine system
    Laporte, Montas
    Charles, Charles M.
    Metelus, Sherly
    Souza, Rafael B.
    Peloggia, Alessandra
    Bahamondes, Luis
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 159 (02) : 577 - 582
  • [8] Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns
    Wittmann, Barbara Zantut
    Monteiro, Ilza
    Juliato, Cassia
    Fernandes, Arlete
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2020, 42 (04): : 194 - 199
  • [9] Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge, Eric T.
    Yigit, Refika
    Molenberghs, Geert
    Straetmans, Dany
    Ombelet, Willem
    CONTRACEPTION, 2007, 76 (02) : 91 - 95
  • [10] Amenorrhea rates during the first year of use Of Liletta™, a new 52 mg levonorgestrel-releasing intrauterine system
    Darney, P.
    Stuart, G. S.
    Thomas, M.
    Cwiak, C.
    Teal, S. B.
    Creinin, M. D.
    CONTRACEPTION, 2015, 92 (04) : 361 - 361